Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt/mammalian target of rapamycin and extracellular signal-related kinase signaling pathways

References

• Palomero T, Dominguez M, Ferrando AA. The role of the PTEN/AKT pathway in NOTCH1-induced leukemia. Cell Cycle 2008; 7:965–970.
   PubMed Web of Science ®Google Scholar
• Gutierrez A, Look AT. NOTCH and PI3K-AKT pathways intertwined. Cancer Cell 2007;12:411–413.
   PubMed Web of Science ®Google Scholar
• Zhang C, Ryu YK, Chen TZ, et al. Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis. Leuk Res 2012;36:342–349.
   PubMed Web of Science ®Google Scholar
• Zhao YM, Zhou Q, Xu Y, et al. Antiproliferative effect of rapamycin on human T-cell leukemia cell line Jurkat by cell cycle arrest and telomerase inhibition. Acta Pharmacol Sin 2008;29:481–488.
   PubMed Web of Science ®Google Scholar
• Batista A, Barata JT, Raderschall E, et al. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors. Exp Hematol 2011;39:457–472.e3.
   PubMed Web of Science ®Google Scholar
• Yu C, Mao X, Li WX. Inhibition of the PI3K pathway sensitizes fludarabine-induced apoptosis in human leukemic cells through an inactivation of MAPK-dependent pathway. Biochem Biophys Res Commun 2005;331:391–397.
   PubMed Web of Science ®Google Scholar
• Steelman LS, Franklin RA, Abrams SL, et al. Roles of the Ras/ Raf/MEK/ERK pathway in leukemia therapy. Leukemia 2011;25: 1080–1094.
   PubMed Web of Science ®Google Scholar
• Hahn M, Li W, Yu C, et al. Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways. Mol Cancer Ther 2005;4:457–470.
   PubMed Web of Science ®Google Scholar
• Romano MF, Avellino R, Petrella A, et al. Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells. Eur J Cancer 2004;40:2829–2836.
   PubMed Web of Science ®Google Scholar
• Laurent G, Jaffrezou JP. Signaling pathways activated by daunorubicin. Blood 2001;98:913–924.
   PubMed Web of Science ®Google Scholar
• Yu HG, Ai YW, Yu LL, et al. Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int J Cancer 2008;122:433–443.
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Abrams SL, Ligresti G, et al. Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. Leukemia 2008;22:2080–2090.
   PubMed Web of Science ®Google Scholar
• Greenberg JM, Gonzalez-Sarmiento R, Arthur DC, et al. Immunophenotypic and cytogenetic analysis of Molt-3 and Molt-4: human T-lymphoid cell lines with rearrangement of chromosome 7. Blood 1988;72:1755–1760.
   PubMed Web of Science ®Google Scholar
• Schneider U, Schwenk HU, Bornkamm G. Characterization of EBV-genome negative “null” and “T” cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int J Cancer 1977;19:621–626.
   PubMed Web of Science ®Google Scholar
• Foley GE, Lazarus H, Farber S, et al. Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 1965;18:522–529.
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27–55.
   PubMedGoogle Scholar
• Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621–681.
   PubMed Web of Science ®Google Scholar
• Nwabo Kamdje AH, Mosna F, Bifari F, et al. Notch-3 and Notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrow-derived mesenchymal stromal cells. Blood 2011;118:380–389.
   PubMed Web of Science ®Google Scholar
• Thomas S, Quinn BA, Das SK, et al. Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets 2013;17:61–75.
   PubMed Web of Science ®Google Scholar
• O’Gorman DM, McKenna SL, McGahon AJ, et al. Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals. Leukemia 2000;14:602–611.
   PubMed Web of Science ®Google Scholar
• Martelli AM, Evangelisti C, Chappell W, et al. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia 2011;25:1064–1079.
   PubMed Web of Science ®Google Scholar
• Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 2011; 36:320–328.
   PubMed Web of Science ®Google Scholar
• De Luca A, Maiello MR, D’Alessio A, et al. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012;16(Suppl. 2):S17–S27.
   PubMed Web of Science ®Google Scholar
• Ivanyi P, Morgan M, Piao W, et al. Pre T-cell receptor alpha (pTalpha) expression patterns and functional analysis in human T-cell lymphoblastic leukemia. Cell Oncol 2010;32:101–108.
   PubMed Web of Science ®Google Scholar
• Zhao YM, Wu KN, Wang YJ, et al. [Synergistic cytotoxic effects of rapamycin and idarubicin on human acute T-cell lymphoblastic leukemia Jurkat cells].Zhejiang Da Xue Xue Bao Yi Xue Ban 2011;40: 482–488.
   PubMedGoogle Scholar
• Weisberg E, Azab AK, Manley PW, et al. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia 2012;26:985–990.
   PubMed Web of Science ®Google Scholar
• Tesfai Y, Ford J, Carter KW, et al. Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy. Leuk Res 2012;36:299–306.
   PubMed Web of Science ®Google Scholar
• Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003;425:841–846.
   PubMed Web of Science ®Google Scholar
• Nwabo Kamdje AH, Krampera M. Notch signaling in acute lymphoblastic leukemia: any role for stromal microenvironment?. Blood 2011;118:6506–6514.
   PubMed Web of Science ®Google Scholar
• Kumagai M, Manabe A, Coustan-Smith E, et al. Use of stroma-supported cultures of leukemic cells to assess antileukemic drugs. II. Potent cytotoxicity of 2-chloro-deoxyadenosine in acute lymphoblastic leukemia. Leukemia 1994;8:1116–1123.
   Web of Science ®Google Scholar
• Umiel T, Friedman S, Zaizov R, et al. Long-term culture of infant leukemia cells: dependence upon stromal cells from the bone marrow and bilineage differentiation. Leuk Res 1986;10:1007–1013.
   PubMed Web of Science ®Google Scholar
• Gluck U, Zipori D, Wetzler M, et al. Long-term proliferation of human leukemia cells induced by mouse stroma. Exp Hematol 1989;17:398–404.
   PubMed Web of Science ®Google Scholar
• Ayala F, Dewar R, Kieran M, et al. Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia 2009;23:2233–2241.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Konoplev S, Hu W, et al. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 2002;16:1713–1724.
   PubMed Web of Science ®Google Scholar
• Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003;17:1175–1182.
   PubMed Web of Science ®Google Scholar
• Fortney JE, Zhao W, Wenger SL, et al. Bone marrow stromal cells regulate caspase 3 activity in leukemic cells during chemotherapy. Leuk Res 2001;25:901–907.
   PubMed Web of Science ®Google Scholar